October 2019

Heart Failure

Endotronix Announces Partnership with Tyndall National Institute.

Endotronix, Latest News / By

Dublin, Ireland.  October 15, 2019.  Seroba’s portfolio company, Endotronix Ireland Limited, a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), announced today an Enterprise Ireland Industry Partnership project in a collaboration with Tyndall National Institute, a leading European Deep Tech research center in integrated ICT (Information and Communications …

Endotronix Announces Partnership with Tyndall National Institute. Read More »

Pq Bypass News

PQ Bypass Announces Unconditional IDE Approval from U.S. FDA for Pivotal Study.

Latest News, PQ Bypass / By

Milpitas, California & Dublin, Ireland.  October 8, 2019.  PQ Bypass Announces Unconditional IDE Approval from U.S. FDA to Start TORUS SFA Stent Graft Pivotal Study (TORUS-2) Seroba’s portfolio company, PQ Bypass, Inc., a clinical-stage medical device company, today announced it has received full approval of its investigational device exemption (IDE) trial of the company’s TORUS …

PQ Bypass Announces Unconditional IDE Approval from U.S. FDA for Pivotal Study. Read More »

Heart Failure

Endotronix Closes Expanded Series D Round.

Endotronix, Latest News / By

Lisle, Illinois & Dublin, Ireland.  Oct 1, 2019.  Seroba’s investee company, Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure (HF), today announced the expansion of its Series D financing round, bringing the total for the round to $70 million. The expansion syndicate for the LSP-led round includes new …

Endotronix Closes Expanded Series D Round. Read More »

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top